Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson’s disease | Zendy

Jenny Ceccarini | Zendy; Cindy Casteels | Zendy; Rawaha Ahmad | Zendy; Melissa Crabbé | Zendy; Laura Van de Vliet | Zendy; Heleen Vanhaute | Zendy; Mathieu Vandenbulcke | Zendy; Wim Vandenberghe | Zendy; Koen Van Laere | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson’s disease

Author(s) -

Jenny Ceccarini,

Cindy Casteels,

Rawaha Ahmad,

Melissa Crabbé,

Laura Van de Vliet,

Heleen Vanhaute,

Mathieu Vandenbulcke,

Wim Vandenberghe,

Koen Van Laere

Publication year - 2019

Publication title -

european journal of nuclear medicine and molecular imaging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.313

H-Index - 163

eISSN - 1619-7089

pISSN - 1619-7070

DOI - 10.1007/s00259-019-04445-x

Subject(s) - superior frontal gyrus , apathy , neuropsychology , orbitofrontal cortex , cognition , parkinson's disease , medicine , precuneus , cognitive flexibility , psychology , executive functions , audiology , neuroscience , psychiatry , prefrontal cortex , disease

The endocannabinoid system plays a regulatory role in a number of physiological functions, including motor control but also mood, emotion, and cognition. A number of preclinical studies in Parkinson's disease (PD) models demonstrated that modulating the type 1 cannabinoid receptor (CB 1 R) may improve motor symptoms and components of cognitive processing. However, the relation between CB 1 R, cognitive decline and behavioral symptoms has not been investigated in PD patients so far. The aim of this study was to examine whether CB 1 R availability is associated with measures of cognitive and behavioral function in PD patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research